Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
3 participants
INTERVENTIONAL
2013-05-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In major population centers, catastrophic events causing mass casualties will disrupt many hospital and emergency services, potentially delaying acute IV fluid resuscitation. Burn patient case reports have shown that oral rehydration therapy (ORT) used to supplement or in place of IV therapy is efficacious. ORT could be easily applied in mass burn casualties.
ORT is generally known in the third world for treating life-threatening dehydration due to diarrhea. The glucose-sodium co transport mechanism enables the affected human intestine to absorb a sufficient amount of water and electrolytes to replace large fluid losses due to severe diarrhea, even under adverse field conditions. No electrolyte disturbances have been recorded in such cases. Studies on enteral resuscitation in animal burn models showed high rates of small intestinal absorption which should be adequate for resuscitation following major burn injury.
The optimal composition of oral rehydration solution for resuscitation in burn wounds has not been determined. In cholera patients, Ceralyte® has proven superior to the World Health Organization Oral Rehydration Solution, increasing fluid absorption of the intestine. The Ceralyte® 90 solution, with 90mEq/L sodium and a low osmolarity of \<275mOsm, may also contribute to optimal intestinal fluid uptake without causing electrolyte disturbances in thermal injury. ORT use might reduce the occurrence of compartment syndrome and pulmonary edema since fluid is regulated by the intestine according to physiologic requirements. The investigators propose to conduct a prospective study using Ceralyte® 90 to show that oral resuscitation therapy (ORT) in burns can reduce the total amount of IV fluid needed for adequate resuscitation and to test the efficacy and safety of ORT in the resuscitation of burn patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thirst-guided Subject-controlled Rehydration in Healthy Volunteers
NCT03932890
Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury
NCT01012648
Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
NCT05612867
Fluid Resuscitation in Burn Patients
NCT03118362
Fluid Resuscitation in Patients Suffering From Burns Injury
NCT01689506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To show that ORT in burns (using Ceralyte® 90) can reduce the total amount of intravenous fluid needed for adequate resuscitation.
* To test the efficacy and safety of ORT in resuscitation of burn patients Secondary objectives.
* To encourage further research on the use of ORT in large thermal injuries and mass casualty situations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ceralyte 90
Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
CeraLyte 90
1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).
2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.
3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.
5\. Patients will be monitored according to standard of care.
a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CeraLyte 90
1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).
2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.
3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.
5\. Patients will be monitored according to standard of care.
a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Partial- to full-thickness burn injuries involving 20-65% of total body surface area (TBSA)
Exclusion Criteria
* Hypotension or shock
* Concomitant serious traumatic injury (i.e. head/ spine trauma)
* Gastric Bypass Surgery
* Small Bowel Obstruction
* Delay in resuscitation \>2 hrs.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephen M Milner, MBBS
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Bayview Burn Center
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Oral Rehydration
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00038778
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.